AstraZeneca

News

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re

Partner Content

Partner Content

Overcoming bottlenecks in early drug discovery with the powe...

Medicines Discovery Catapult and AstraZeneca collaborate to unlock the potential of Acoustic Mist Ionisation Mass Spectrometry

News

Clovis hopes to get ahead of rivals in prostate cancer with ...

Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca an

News

Pfizer's Talzenna PARP breast cancer drug approved in US

The US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation.

News

AZ to continue with investment freeze following 'no deal' Br...

AstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide clarity on future trading relations, according to press reports.

News

Novo Nordisk poaches AZ's Helfgott to run Biopharm business

Novo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia and human growth hormone franchises.

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

Overcoming bottlenecks in early drug discovery with the powe...

Clovis hopes to get ahead of rivals in prostate cancer with ...

Pfizer's Talzenna PARP breast cancer drug approved in US

AZ to continue with investment freeze following 'no deal' Br...

Novo Nordisk poaches AZ's Helfgott to run Biopharm business

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

AstraZeneca

Editor's Picks